SI-BONE, Inc. (NASDAQ:SIBN) Given Average Recommendation of "Buy" by Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) have been assigned an average rating of "Buy" from the six analysts that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year is $22.67.

Several equities research analysts recently issued reports on the company. Needham & Company LLC decreased their price target on SI-BONE from $27.00 to $19.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Truist Financial reduced their target price on shares of SI-BONE from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Monday, October 14th. Finally, Morgan Stanley dropped their price target on shares of SI-BONE from $21.00 to $19.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th.

SI-BONE Stock Up 6.8 %

Shares of SIBN traded up $0.84 during trading hours on Tuesday, reaching $13.11. The stock had a trading volume of 1,226,424 shares, compared to its average volume of 385,864. The company has a current ratio of 9.17, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22. The firm has a 50-day simple moving average of $14.51 and a 200 day simple moving average of $14.37. SI-BONE has a 12 month low of $11.76 and a 12 month high of $21.70. The company has a market capitalization of $546.61 million, a price-to-earnings ratio of -11.26 and a beta of 1.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. The company had revenue of $39.97 million during the quarter, compared to the consensus estimate of $38.95 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. Equities research analysts predict that SI-BONE will post -0.89 earnings per share for the current fiscal year.

Insider Activity at SI-BONE

In other news, insider Anthony J. Recupero sold 3,305 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the completion of the transaction, the insider now directly owns 233,412 shares of the company's stock, valued at $3,169,734.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the completion of the sale, the insider now owns 233,412 shares of the company's stock, valued at approximately $3,169,734.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Laura Francis sold 9,967 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.84, for a total transaction of $137,943.28. Following the transaction, the chief executive officer now owns 492,923 shares of the company's stock, valued at $6,822,054.32. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,019 shares of company stock worth $349,879. 5.40% of the stock is owned by company insiders.

Institutional Trading of SI-BONE

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in SI-BONE by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company's stock worth $40,328,000 after acquiring an additional 43,670 shares during the last quarter. Champlain Investment Partners LLC grew its stake in SI-BONE by 104.8% in the 1st quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company's stock worth $40,158,000 after buying an additional 1,255,610 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of SI-BONE by 22.8% in the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company's stock worth $25,685,000 after buying an additional 368,637 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its holdings in shares of SI-BONE by 24.7% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company's stock worth $17,448,000 after acquiring an additional 267,100 shares during the last quarter. Finally, Bellevue Group AG grew its position in SI-BONE by 810.5% in the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company's stock worth $18,661,000 after acquiring an additional 1,014,756 shares in the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.